Liposomal amphotericin B: clinical experience and perspectives
Authors:
- Winter J GibbsWGWinter J Gibbs
- Richard H DrewRDRichard H Drew
- John R PerfectJPJohn R Perfect
- 1 April 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 3 (2) , 167-181
Abstract
While amphotericin B deoxycholate (Fungizone, Apothecon Pharmaceuticals) has been considered by many to be the gold standard for the treatment for numerous invasive fungal infections for over 45 years, toxicities associated with its use often necessitate treatment modification or discontinuation. Lipid-based formulations, including liposomal amphotericin B (AmBisome, Fujisawa Healthcare, Inc.), were developed to decrease many of these toxicities while retaining broad antifungal spectrum and potency of amphotericin B. In clinical trials, liposomal amphotericin B has demonstrated efficacy comparable to that of amphotericin B deoxycholate while reducing the incidence of treatment-related nephrotoxicity, electrolyte-wasting, and infusion-related reactions. In addition, recent clinical trials have also compared liposomal amphotericin B with other antifungal classes. Acquisition costs of liposomal amphotericin B are substantially higher than those of amphotericin B deoxycholate and other antifungals. While pharmacoeconomic analyses consider outcomes and other treatment-related costs, they have yet to clearly demonstrate the cost-effectiveness of liposomal amphotericin B when compared with amphotericin B deoxycholate or other antifungal agents. This review will focus primarily on recent liposomal amphotericin B experience and attempt to put its use into perspective considering other available antifungal agents.Keywords
This publication has 101 references indexed in Scilit:
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal InfectionsPharmacoEconomics, 2004
- Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological CharacteristicsClinical Infectious Diseases, 2003
- Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open‐Label Observational StudyClinical Infectious Diseases, 2003
- A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2002
- Mortality and Costs of Acute Renal Failure Associated with Amphotericin B TherapyClinical Infectious Diseases, 2001
- A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile NeutropeniaClinical Infectious Diseases, 2000
- Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Lipid-based amphotericin B in the treatment of cryptococcosisInfection, 1994
- Liposomal and Lipid Formulations of Amphotericin BClinical Pharmacokinetics, 1992